Floatz logo

ETOPOSIDE

Recurrent Childhood Acute Myeloid Leukemia

Joanna YiSmall moleculePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Recurrent Childhood Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Washington University School of Medicine
Phase 3BB
Cyclophosphamide
Joanna Yi
Phase 3BB
Fludarabine
Joanna Yi
Phase 3BB
Romidepsin
Washington University School of Medicine
Phase 3BB
Cediranib
National Cancer Institute (NCI)
Phase 3BB

View all 43 →

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →